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Abstract: Bladder cancer is a un ique  disease process in  th a t c lin ica lly  s ign ifican t 
hem orrhage  can occur s im u ltaneous ly  w ith  equa lly  s ig n ifica n t abe rran t c lo t­
tin g . W ith  hem atu ria  th e  key p resen ting  sym p tom  o f b ladder cancer, h em or­
rhage is genera lly  th o u g h t to  be a co m p o n e n t o f th e  natura l h is to ry  o f th e  d is­
ease, and to  co m m o n ly  occu r d u rin g  its tre a tm e n t. However, as those  w ho  
regu la rly  tre a t b ladde r cancer know , th e  need to  address a p red ispos ition  to  
c lo ttin g  is also very m uch p a rt o f th e  tre a tm e n t parad igm . Physicians m ust be 
co g n izan t o f th e  b iochem ica l changes th a t con fe r a p ro p e n s ity  fo r b o th  s ig n ifi­
can t b leed ing  and c lo ttin g  occu rring  s im u ltaneous ly  in th e ir  pa tien ts. Both o f 
these en titie s  rem ain im p o rta n t issues, and fu r th e r s tudy is needed to  fin d  ways 
to  m itig a te  and balance th e  associated risks. Here, w e pe rfo rm ed  a review  o f the  
lite ra tu re , focus ing  on th e  co n co m ita n t issues o f  b leed ing  and venous th ro m ­
boem bo lism  in b o th  th e  p re - and pos t-ope ra tive  periods in pa tien ts  w ith  b lad ­
der cancer. We fo rm u la te d  a genera l m anagem en t approach  w ith  respect to  
these tw o  processes, and we p rov ide  d ire c tio n  fo r fu r th e r inves tiga tion .
In tro d u c tio n
Cancer has long been recognized as 
a risk factor for thrombotic events. 
While venous thromboembolism 
(VTE, which includes pulmonary em­
bolism [PE] and deep vein thrombosis 
[DVT]) is clearly the most common 
form of malignancy-associated throm­
bosis, arterial thrombosis and systemic 
thrombotic syndromes (eg, dissemi­
nated intravascular coagulation [DIC]) 
can also occur. Overall, approximately 
2% of patients with bladder cancer 
(BCa) will experience a VTE event, a 
rate five times higher than that in the 
overall population; also, such an event 
results in a threefold increased risk of 
death in patients with cancer.[1-3]
It is perhaps unusual that BCa is 
also strongly associated with bleed­
ing phenomena. For example, hema­
turia is present in virtually all patients
with bladder tumors and is the most 
common presenting symptom of BCa. 
Likewise, anemia is present in many pa­
tients with BCa, and the most common 
complication of radical cystectomy is 
anemia requiring blood transfusion. [4] 
Physicians who manage BCa are there­
fore commonly faced with clinical sce­
narios in which bleeding and clotting 
risks must be balanced. In this article 
we will review how BCa dysregulates 
hemostasis, describe the important 
clinical sequelae of this dysregulation, 
and discuss some strategies for clinical 
management of these sequelae.
Physiologic C oagu lation  and  
Fibrinolysis
Damaged blood vessels seal themselves 
through the natural process of coagu­
lation that results in fibrin clot forma­
tion. The normal coagulation cascade,
depicted in Figure 1, comprises three 
pathways: (1) the intrinsic contact acti­
vation pathway; (2) the extrinsic tissue 
factor pathway; and (3) the final com­
mon pathway, where the intrinsic and 
extrinsic pathways converge.
Normally, the extrinsic tissue factor 
pathway is the primary pathway for the 
initiation of coagulation and is mea­
sured by the prothrombin time (PT) 
and the related international normal­
ized ratio (INR). Tissue factor (TF, fac­
tor III) is a cell surface protein found on 
leukocytes and subendothelial cells (eg, 
fibroblasts) and is the only protein in 
the clotting cascade for which an inher­
ited congenital deficiency has not been 
found. With blood vessel injury, cells in 
the subendothelial space become ex­
posed to circulating plasma proteins, 
including the factor VII zymogen, an 
inactive protease and the most abun­
dant coagulation factor found in the 
blood. Factor VII binds TF, and togeth­
er they become an active serine prote­
ase complex known as extrinsic tenase, 
which activates factors IX and X. Tissue 
factor pathway inhibitor (TFPI) inhibits 
both the VIIa-TF complex and Xa, and 
is therefore an important physiologic 
mechanism for regulating the extrinsic 
tissue factor pathway.
The intrinsic contact activation 
pathway, measured by the activated 
partial thromboplastin time (aPTT), is 
activated when blood vessel injury spills 
plasma proteins onto subendothelial 
collagen fibers. Several coagulation fac­
tors—including factor XII (Hageman 
factor), high-molecular weight kinino- 
gen (HMWK), and prekallikrein—bind 
to the collagen fibers and become acti­
vated. Factor Xlla then activates factor 
XI, which in turn activates factor IX'Division of Urology, Duke University Medical Center, Durham, North Carolina
cancernetwork.com ONCOLOGY . October 2014 8 4 7
Thromboembolism and Bleeding in Bladder Cancer
Figure 1: The Coagulation Cascade—Ca = calcium; FDPs = fibrin degradation products; 
PAI-1 = plasminogen activator inhibitor—1; PL = phospholipid;TF = tissue factor; tPA = tissue 
plasminogen activator.
(Christmas factor). In the presence of 
calcium and membrane phospholipids, 
factor IXa binds to factor Villa to form 
the intrinsic tenase complex. Factor 
IXa is physiologically inhibited by anti­
thrombin (AT), while factor Villa is 
inhibited by activated protein C (APC). 
Although factor XII is used in vitro to 
activate coagulation, in vivo its defi­
ciency is asymptomatic. Deficiencies of 
factors VIII, IX, and XI lead to hemo­
philias A, B, and C, respectively.
The intrinsic and extrinsic pathways 
converge on the common coagulation 
pathway since both produce a “tenase” 
that activates factor X. Factor Xa and 
factor Va join to form the prothrombi- 
nase complex that converts prothrom­
bin (factor II) to thrombin. Thrombin 
then cleaves the soluble fibrinogen 
(factor I) into insoluble fibrin strands 
that are then covalently cross-linked 
by factor XHIa to form a blood clot. 
Physiologic inactivation of the com­
mon coagulation pathway occurs by 
APC inhibition of factor Va, and by AT 
inhibition of factor Xa and thrombin. 
Factor V deficiency causes parahemo­
philia, while certain point mutations 
in the factor V gene lead to a hyperco- 
agulable state called factor V Leiden. 
Whereas congenital deficiencies of fac­
tor X, prothrombin, or fibrinogen are 
exceedingly rare, acquired deficiencies 
of factor X occur with hemodilution 
(eg, blood loss), consumptive patholo­
gies (eg, sepsis, trauma, DIC), and liver 
disease.
The last component of physiologic 
coagulation is fibrinolysis, the process 
that prevents overabundant clotting 
and removes clots once healing has 
occurred. Soon after the coagulation 
cascade has begun, the fibrinolytic cas­
cade (Figure 2) is activated to eventu­
ally break down the clot once the vessel 
is repaired. The key enzyme control­
ling fibrinolysis is plasmin, which is 
activated from plasminogen by tissue 
plasminogen activator (tPA), urokinase 
plasminogen activator (uPA), and fac­
tors XIa and Xlla. The most important 
plasminogen activator is tPA, which is 
slowly released by the endothelium of 
the injured blood vessel. Once active, 
plasmin cleaves the fibrin clot into fi­
brin degradation products (FDPs), the 
most clinically important of which is 
the D-dimer. Fibrinolysis is regulated 
by several mechanisms. First, uPA and 
tPA are inhibited by the plasminogen 
activator inhibitors (PAI-1 and PAI-2). 
Second, plasmin itself is inhibited by 
the plasma proteins a2-antitrypsin and 
a2-macroglobulin. Lastly, the fibrin clot 
is protected by thrombin-activatable fi­
brinolysis inhibitor (TAFI, also known 
as carboxypeptidase U), an enzyme 
that is activated by thrombin and that 
removes from the fibrin strands the C- 
terminal residues that are required for 
binding of plasminogen to the clot.
A lte ra t io n s  in  C o a g u la t io n  a n d  
F ib rin o ly s is  in  B la d d e r  C a n c e r
It has been recognized for decades that 
abnormalities in coagulation and fibri­
nolysis are present in BCa.[5-7] These 
abnormalities have been exploited as 
both diagnostic and prognostic bio­
markers, and for therapeutic targeting. 
Note that these molecular alterations 
are both pro-thrombotic and pro-fibri­
nolytic.
Tissue factor (TF)
TF controls the extrinsic coagulation 
pathway but also has biologic effects 
that promote angiogenesis and metas­
tasis. Urinary and serum TF levels are 
elevated in patients with BCa.[8-10] 
Importantly, TF is overexpressed in 
approximately 75% of muscle-invasive 
BCas and is associated with a threefold 
increased risk of death. [11]
Urokinase plasm inogen activa to r (uPA)
Although its primary role is to acti­
vate fibrinolysis, uPA also plays a role 
in BCa. First, uPA and its receptor are 
produced by cultured BCa cells and fa­
cilitate their invasiveness. [12] Second, 
uPA and its RNA are elevated in the 
urine of BCa patients. [13,14] Third, 
uPA is overexpressed in BCa and as­
sociated with a higher recurrence rate 
and worse survival. [15,16] Interesting­
ly, intravesical uPA has been used (in-
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Figure 2: The Fibrinolytic Cascade— FDPs = f ib r in  deg rada tion  p roducts; PAI =  p lasm ino ­
gen a c tiva to r in h ib ito r; TAFI =  th ro m b in -a c tiva ta b le  fib rino lys is  in h ib ito r; tPA = tissue plas­
m inogen  activa tor; uPA =  urokinase p lasm inogen  activator.
effectively) in combination with doxo­
rubicin and thioTEPA as intravesical 
treatment for BCa.[17-19] Drugs that 
target uPA and its receptor (uPAR) are 
being developed.[20]
Plasminogen activator inhibitor- 7 
(PAI-1)
In addition to inhibiting fibrinolysis, 
PAI-1 (also known as SERPINE1) is 
involved in angiogenesis, cell migra­
tion, and cell adhesion. It is overex­
pressed in BCa and its levels in urine 
and serum appear to increase with tu­
mor stage.[21,22] The presence of even 
a single cell expressing PAI-1 has been 
shown to increase BCa-specific mor­
tality 4.5-fold.[22] Targeting PAI-1 
was shown to be an effective anticancer 
therapy in a BCa xenograft model.[23]
Fibrinogen and fibrinogen degradation 
products (FDPs)
FDPs are elevated in the urine of pa­
tients with BCa and are indicative of 
increased fibrinolysis. [24-26] Intraves­
ical fibrinogen has been administered 
with the bacillus Calmette Guerin 
(BCG) vaccine in an attempt to im­
prove the efficacy of the BCG. [27]
V e n o u s  T h ro m b o e m b o lis m  in  
B la d d e r  C a n c e r
VTE occurs in 1% to 2% of BCa pa­
tients within 2 years of their initial di­
agnosis, which is a rate 5-fold higher 
than that of the overall population. [1] 
This rate is markedly affected by pa­
tient factors such as age, disease stage, 
and type of cancer treatment (Table 1). 
Importantly, the occurrence of VTE is 
a prognostic factor—independent of 
age, BCa stage, and comorbidity—that 
triples the mortality risk in patients 
with BCa.[l]
Several risk-assessment tools are 
available to help predict the risk of 
VTE. For cancer patients, the Khorana 
score can be used to predict the prob­
ability of VTE and is currently recom­
mended for use in guidelines from the 
American Society of Clinical Oncol­
ogy (ASCO), the European Society for 
Medical Oncology (ESMO), and the 
National Comprehensive Cancer Net­
work (NCCN).[28] The Khorana score 
ranges from 0 to 7 points and the cu­
mulative 6-month probability of VTE 
is approximately 1% for patients at the 
lowest risk of VTE (a score of 0), 5% 
for low- to intermediate-risk patients 
(a score of 1), 10% for intermediate- 
risk patients (a score of 2), and 20% 
for high-risk patients (a score > 3). The 
Caprini score, another tool for predict­
ing VTE, is also applicable to patients 
without cancer; it is more useful for 
perioperative risk assessment and is 
recommended in the 2012 American 
College of Chest Physicians (ACCP) 
VTE guidelines. [29]
Bladder cancer is one of several 
cancer types for which patients are 
considered to be at high risk of devel­
oping VTE.[30] Sandhu et al produced 
a study of nearly 25,000 patients with 
BCa that revealed a 2-year cumula­
tive incidence of VTE of 1.9%.[1] The 
highest incidence was within the first 
6 months following diagnosis. Risk of 
VTE was increased by the presence of 
metastatic disease at the time of diag­
nosis, with a 15.3% incidence of VTE in 
the first 6 months. The authors found, 
however, that cystectomy conferred a 
2.1-fold increase in the risk of develop­
ing VTE compared with patients who 
did not undergo surgery. This is in 
stark contrast to other major surgically 
treated malignancies such as breast, 
lung, and colorectal cancer, in which 
the risk of VTE is decreased following 
surgical treatment. [1,31-33] A limi­
tation in Sandhu’s study is that those 
undergoing systemic chemotherapy or 
using chronic anticoagulation were not 
identified for subgroup analysis. Some 
potential reasons for the increased risk 
of VTE in post-cystectomy patients are: 
the complexity of pelvic surgery, ex­
tensive lymphadenectomy, prolonged 
procedure, extended time in lithotomy 
position, and perhaps biochemical al­
terations in the coagulation cascade 
due to the malignancy itself. The com­
parison to other solid tumors associat­
ed with a lower incidence of VTE may 
also be biased, given that patients who 
were offered surgery may have been at 
a lower risk of VTE in general.
As shown in Table 1, the risk of VTE 
in patients undergoing treatment with 
systemic chemotherapy ranges from 
3.3% to 21%.[30,34-37] Multiple stud-
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■ F l i l E H  Approximate Incidence of Venous Thromboembolism in 
Bladder Cancer
Rate (Range) References
Overall Incidence 1.3%-1.9% Sandhu et al[1 ]; Blom et al[64]
Age (yr) Sandhu et al[1]
<45 1.2%
45-64 1.7%
65-74 2.1%
>75 1.9%
Disease Stage Sandhu et al[1]
Localized 1.3%
Regional 6.2%
Metastatic 6.3%
Treatment
Cystectomy 6% (2.9%-24%) VanDlac et al[44]; Clement et al[65]; 
Dyer et al[66]
Systemic chemotherapy 3.3%—21 % Khorana et al[30]; Agnelli et al[34]; 
Czaykowski et al[35]; Hahn et al[36]; 
Haggag et al[37]
ies have looked at the incidence of VTE 
in this setting, and have identified risk 
factors for its development. In a study 
of 271 BCa patients undergoing cispla- 
tin-based therapy, 35 (12.9%) experi­
enced a “vascular event.” There were 18 
DVT events, 9 PEs, 7 cases of arterial 
thrombosis, 3 strokes, and one case of 
superficial thrombophlebitis. Risk fac­
tors included a pelvic mass, existing pe­
ripheral vascular disease, and coronary 
artery disease. [35] A lower-dose regi­
men of gemcitabine and cisplatin was 
compared to standard dosing in a phase 
II trial in 2014 that revealed a DVT/PE 
rate of 3.3% in both arms.[37] Howev­
er, with new therapies being instituted, 
such as bevacizumab, the toxicity pro­
file will change in patients undergoing 
systemic chemotherapy. In the phase 
II trial of gemcitabine, cisplatin, and 
bevacizumab, an impressive 21% of pa­
tients experienced a DVT or PE. [36] 
The ACCP, ASCO, ESMO, and 
NCCN guidelines recommend VTE 
prophylaxis with low-molecular-weight 
heparin (LMWH) or low-dose heparin 
(LDH) for hospitalized patients with 
active BCa who are not at significant 
risk of bleeding. [38-41] For hospital­
ized patients at risk of bleeding, gradu­
ated compression stockings (GCS) or 
intermittent pneumatic compression 
(IPC) is recommended. Note that rou­
tine prophylaxis is not recommended 
for ambulatory patients with BCa who 
are receiving outpatient chemotherapy, 
even those who have had a central ve­
nous catheter placed.
For BCa patients undergoing sur­
gery, VTE prophylaxis recommen­
dations are a bit more complicated. 
For minor outpatient procedures like 
transurethral resection of bladder tu­
mor (TURBT), early ambulation alone 
is recommended in the American 
Urology Association (AUA) and ACCP 
guidelines because the VTE risk is very 
low.[42,43] However, radical cystec­
tomy poses a much higher risk of VTE, 
and the ACCP, ASCO, AUA, ESMO, 
and NCCN guidelines all recommend 
pharmacologic prophylaxis (with 
LMWH the favored agent) as the pri­
mary means of VTE prevention, with 
IPC or GCS as a secondary method. 
[38-40,42,43] Importantly, pharma­
cologic prophylaxis should be started 
prior to surgical incision and should 
continue for 4 weeks postoperatively. 
[39,40] This is because VTE occurs at 
a median of 14 days postoperatively
from cystectomy, implying that at least 
50% of VTE events will occur after dis­
charge. [44] If an epidural catheter is 
used for postoperative pain control, it 
should be placed prior to preoperative 
administration of heparin, and LDH is 
generally preferred over LMWH (al­
though LMWH is still an option) as 
long as the epidural catheter is in place, 
because LDH has a shorter duration of 
action and is associated with a lower 
rate of epidural hematoma. [45] Rou­
tine screening for VTE with Doppler 
ultrasonography in postoperative BCa 
patients is not recommended. [43]
Bleeding in Bladder Cancer
Hematuria is the characteristic sign 
that typically leads to detection of BCa. 
[46] Up to 85% of patients with newly 
diagnosed BCa have gross hematuria, 
and virtually all have microscopic he­
maturia. [47-49] While 15% to 20% of 
patients with gross hematuria will have 
BCa, the risk of BCa in patients with 
microscopic hematuria is only 1% to 
5%. [46-48,50] BCa-induced hematuria 
can also present more acutely as profuse 
bladder hemorrhage. Such cases require 
admission for bladder irrigation (usual­
ly with a three-way catheter and saline, 
although bladder irrigation is some­
times achieved with hemostatic irriga­
tion solutions), red blood cell (RBC) 
transfusion, and occasionally operative 
intervention. The most common opera­
tive procedures include cystoscopic clot 
evacuation and transurethral fulgura- 
tion, with or without tumor resection. 
In rare cases of severe bleeding, intra­
vesical formalin, bladder angioembo- 
lization, or urgent cystectomy may be 
indicated. [51]
A second scenario in which bleed­
ing is encountered is during the surgical 
management of BCa. After TURBT, 1% 
to 2% of patients require a RBC transfu­
sion and 0.5% to 2.5% require a second 
clot evacuation/hemostasis procedure. 
[52,53] Approximately 5% of patients 
are readmitted after TURBT, and bleed­
ing requiring transfusion accounts for
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B i l u k r l  M ethods for Reducing Blood Loss and the Need for 
Perioperative Transfusion During Cystectomy in Patients W ith Bladder 
Cancer
Preoperative Com m ents References
Erythropoietin Safe and reduces transfu­
sion rates in patients 
undergoing chemotherapy. 
Safe and effective means of 
reducing allogeneic blood 
transfusions.
Albers et al[67]; Case et 
et al[68]; Dunphy et 
a I [69]
Blood banking Safe and shown to be 
effective in reducing 
need for allogeneic blood 
transfusion.
Maegawa etal[70]; 
Hayakawa et al[71 ]
Surgical
Pedicle management Stapler equivalent to 
LigaSure. (LigaSure is less 
expensive.)
Stapler superior to suture- 
ligature.
Thompson etal[57]; 
Chang et al[72]
Autotransfusion using Appears oncologically safe, Ubee et al[73]; Niederet
Cell Saver probably reduces transfu­
sion rate, cheaper than 
transfusion.
al[74]; Aning et al[75]; 
Ashworth et al[76]; 
Davies et al[77]
Fibrin sealant Frequently used by sur­
geons. Studies showing 
quantitative benefit in 
humans, such as reduction 
in transfusions, are lacking.
Punjani et al[78]; 
Seyednejad et al[79]
Anesthesia/M edical
Permissive hypotension Intraoperative hypotension 
reduces blood loss.
Ahlering et al[80]; 
Ryan[81]
Normovolemic
hemodilution
Unclear whether transfu­
sions are reduced.
Gille et al[82]; Takayanagi 
et al[83]
Fibrinogen infusion Fibrinogen reverses the 
coagulopathy caused by 
hydroxyethyl starch infu­
sion and reduces the need 
for blood transfusions.
Fenger-Eriksen et al[84]
Fibrinolysis inhibitors 
(tranexamic acid, amino- 
caproic acid, aprotinin)
Tested in a variety of surgi­
cal contexts, these agents 
reduce transfusions by 40%. 
[85] A randomized trial 
of tranexamic acid is under­
way for cystectomy 
(NCT01869413).
Factor VII No data for cystectomy. 
Very costly.
Desmopressin No data for cystectomy.
3% of these readmissions. [54] Bipolar 
resection causes less blood loss than 
monopolar resection. [52]
Blood loss is a significantly bigger 
problem for patients managed with 
radical cystectomy, however. For open 
cystectomy, the median blood loss vol­
ume is 500-1,000 mL, the median rate 
of RBC transfusion is 40% to 70%, and 
the median number of transfused RBC 
units is 2. [4,55-58] The amount of blood 
loss in patients who undergo robotic/ 
laparoscopic cystectomy is approxi­
mately half that of open cystectomy; 
consequently, the transfusion rate is 
quite a bit lower. [55,59] The transfusion 
rate is clearly affected by neoadjuvant 
chemotherapy, which is standard of care 
for muscle-invasive BCa, since these pa­
tients are often anemic preoperatively 
after chemotherapy. Several studies have 
shown a 15% to 30% increased risk of 
cancer-specific and overall mortality in 
patients who receive perioperative RBC 
transfusions at cystectomy. [4,56,58] 
While a variety of immune mechanisms 
have been proposed to explain this phe­
nomenon, we believe that the relation­
ship between transfusion and outcome 
is clearly confounded by disease sever­
ity, which may not be fully captured by 
the clinical variables currently consid­
ered in survival models.
Regardless of whether RBC trans­
fusion worsens cancer outcomes, it is 
still desirable to reduce the number of 
transfusions performed, since they are 
expensive and increase the risk of ad­
verse events such as allergic transfusion 
reactions, transfusion-associated lung 
injury, and infections. [60] Several ap­
proaches to reducing blood loss from 
cystectomy and/or the need for RBC 
transfusions are described in Table 2.
As mentioned previously, a number 
of biochemical changes in the coagula­
tion and fibrinolytic cascades occur in 
the setting of BCa. Clinical evidence of 
these changes is of course the hematuria 
seen at presentation; however, systemic 
derangements can be seen as well. De 
novo development of DIC with micro­
vascular thrombosis is a known entity in 
BCa. There have been multiple case re­
ports of DIC occurring in patients with
BCa, particularly after tumor manipu­
lation (ie, surgical intervention). This 
phenomenon is also seen in other solid
cancernetwork.com ONCOLOGY . October 2014 851
T h ro m b o e m b o lis m  a n d  B leed in g  in B la d d e r C ancer
tumors, and several mechanisms have 
been proposed to explain how it may oc­
cur. TF is believed to play a role, as it is 
overexpressed in bladder cancer. Its in­
teraction with factor Vila triggers both 
prothrombinase and tenase complexes 
that will generate thrombin and lead to 
DIC with coagulation factor consump­
tion. Another proposed mechanism is 
overexpression of urokinase, which may 
add to the fibrinolytic activity leading to 
increased bleeding. Another risk factor 
is the presence of necrosis within the tu­
mor, which creates endothelial cell dam­
age, triggering the intrinsic coagulation 
pathway within its microenvironment. 
The activation of this pathway may lead 
to aberrant shifts in hemostasis, such as 
development of DIC and consequent 
consumptive coagulopathy. [61-63]
Conclusions
In the treatment of BCa, it is essential 
that the clinician take into account 
the entire hemostatic spectrum, from 
bleeding to clotting. Hematuria is the 
hallmark of BCa, and is seen in nearly 
100% of diagnosed cases. In reviewing 
the literature, it became clear that the 
proper clinical approach to patients 
with hematuria who are at risk for BCa 
is not taken as frequently as we would 
expect. Improper management intro­
duces the potential for missed diagno­
ses and delays in treatment, which are 
especially problematic in BCa patients 
with high-grade disease. As a urologic 
community we must raise awareness 
about the clinical implications of he­
maturia, and ensure that the proper 
patient workup and referrals are being 
carried out.
Operative blood loss is unavoid­
able in both endoscopic and extirpative 
treatment of BCa. Urologists perform 
a wide array of outpatient procedures, 
and the literature reviewed in this article 
indicates that TURBT is the most com­
mon procedure in this setting. In turn, 
the most common reason for readmis­
sion following TURBT has been devel­
opment of gross hematuria requiring
bladder irrigation. This likely mirrors 
the practice patterns of many general 
urologists working in the community 
setting. Avoidance of this particular 
problem will vary from one institution 
to another, depending on whether it is 
a low-volume or a high-volume center, 
a teaching or non-teaching hospital, or 
a community-based private practice. 
However, adequate resection with ag­
gressive intraoperative hemostatic con­
trol using bipolar cautery will be para­
mount in all of these settings.
Controlling blood loss in radical 
cystectomy will continue to be a sub­
ject of debate in the urologic literature, 
and one of the major talking points 
among proponents of robot-assisted 
surgery. In the reviewed publications, 
the transfusion rates were quite high 
for patients managed with open radical 
cystectomy. Given these rates, coupled 
with the potential risks of transfusion 
reactions and perhaps even a negative 
oncologic effect of allogeneic blood 
products, strategies for reducing blood 
loss are going to be continually sought 
after. It is our opinion that experienced 
surgeons working in high-volume insti­
tutions will be able to achieve the best 
clinical outcomes, due to the multidis­
ciplinary ancillary support available at 
such centers, and the complex nature 
of the surgery. Adjunctive treatments, 
such as cell-salvage, blood banking, im­
proved vascular pedicle management, 
and systemic clotting agents, may be of 
some clinical benefit in the periopera­
tive period. Minimally invasive robotic 
surgery does appear to have impressive 
perioperative outcomes; however, the 
oncologic durability of this procedure is 
not entirely clear at this time. Given that 
the treatment goal is removal of the ma­
lignant process with subsequent cancer- 
free survival, this is the measure that 
should be used to determine the long­
term success of the procedure. Further 
investigation into the use of intra­
operative systemic hemostatic agents, 
such as desmopressin, tranexamic acid, 
factor 7, and aminocaproic acid, which
have proven useful in other surgical 
contexts, is needed in cystectomy. How­
ever, the risk of undesirable thrombo­
sis attributable to these pharmacologic 
agents must be taken into consideration 
along with the underlying propensity 
for clot formation in patients with BCa.
Reliable evidence of biochemical al­
terations in both the coagulation and 
fibrinolytic cascades has been reported 
in the setting of BCa. Some of these al­
tered molecules are even the targets of 
treatments now under development, 
given their association with more ag­
gressive disease. These alterations do 
seem to translate to clinical conse­
quences in the management BCa, rang­
ing from fulminant DIC to PE. The 6% 
rate of VTE post radical cystectomy, 
with 20% of VTEs being fatal despite 
appropriate prophylaxis, [64] shows us 
that aberrant clotting in this setting can 
have devastating clinical consequences. 
Early ambulation, institution of DVT 
chemoprophylaxis as soon as feasible, 
and awareness by the treatment team 
that VTE is a risk should be the corner­
stones of VTE prevention and early rec­
ognition. VTE in the setting of systemic 
chemotherapy is also of great concern, 
and is likely due in part to both the dis­
ease process itself and the toxicity of the 
agent. Screening for DVT in the set­
ting of advanced BCa is not of benefit 
at this time. There is a need for further 
work on the development of novel pro­
phylaxis approaches, preoperative risk 
stratification, and perhaps preoperative 
interventions to reduce the incidence 
of postoperative clotting. All of these 
investigations must take into consider­
ation the propensity of bleeding in this 
population and weigh it against their 
aberrant clotting risk. O
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Venous Thromboembolism and 
Bleeding Risk in Bladder Cancer
ARUN Z. TH O M A S, M D 1 
ASHISH M . KAMAT, M D 1
Venous thromboembolism ([VTE] including deep venous thrombosis [DVT] and pulmonary em­
boli [PE]) occurs with an annual incidence of 160 per 
100,000 within the general population in North Ameri-
1 Department of Urology, The University of Texas MD 
Anderson Cancer Center, Houston, Texas
ca, and DVT and PE carry an annual economic burden 
of $33,000 and $3,200, respectively, per patient. [1,2] 
While VTE events are uncommon in the general popu­
lation, the risk of developing a VTE rises substantially 
with an increase in the number of operative procedures, 
patient age, and medical comorbidities, and is exacer­
bated in patients with cancer.
To reduce the risk of VTE, thromboprophylactic 
measures in the form of chemical anticoagulation (hep­
arin, low-molecular-weight heparin [LMWH]), me­
chanical prophylaxis (compression stockings, sequential 
compression devices), and early postoperative mobiliza­
tion have been implemented in clinical practice. Despite 
these management approaches, there is little consensus
854 ONCOLOGY . October 2014 cancernetwork.com
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